NCT02268383View on ClinicalTrials.gov

Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 9, 2014

Primary Completion Date

March 19, 2020

Study Completion Date

March 19, 2020

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Luspatercept

Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.

Trial Locations (1)

Unknown

Acceleron Investigative Site, Dresden

All Listed Sponsors
lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT02268383 - Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) | Biotech Hunter | Biotech Hunter